BTIG analyst Mark Massaro lowered the firm’s price target on Caris Life Sciences (CAI) to $38 from $45 due to multiple compression but keeps a Buy rating on the shares. The company delivered a strong 2025 and set a solid bar for 2026 which sets up to be another good year for growth and its pipeline, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target raised to $28 from $26 at Baird
- Caris Life Sciences price target lowered to $35 from $40 at JPMorgan
- Caris Life Sciences price target lowered to $35 from $42 at Citi
- Caris Life Sciences reports Q4 EPS 28c, consensus 10c
- Caris Life Sciences sees 2026 revenue $1.0B-$1.02B, consensus $979.7M